Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world claims analysis data at the ISPOR 2026 conference, revealing the significant clinical and economic burden of fibromyalgia in U.S. adults. The findings, based on a retrospective analysis of more than 261,000 adult patients, show high rates of comorbidities, extensive healthcare resource utilization, and widespread reliance on multimodal treatment approaches.
According to the data, more than 93% of fibromyalgia patients had at least one fibromyalgia-related comorbidity, highlighting the complexity of managing the condition. Insured patients incurred substantial annual healthcare costs, driven primarily by inpatient services. These findings underscore the unmet need for more effective long-term treatment options as Tonix advances its planned commercial launch of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company's recently approved flagship medicine for fibromyalgia.
TONMYA represents the first new treatment for fibromyalgia in more than 15 years, offering a novel therapeutic option for patients who have long faced limited choices. The real-world data presented at ISPOR 2026 further validate the heavy disease burden and the urgent need for innovative therapies. Tonix is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, expanding its potential applications.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. Beyond fibromyalgia, Tonix's pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
For more information, visit the company's newsroom at https://ibn.fm/TNXP.
